Close Menu

stock price

The company said that CMS will correct a clinical lab fee schedule that set reimbursement for the Cologuard test well below the amount set in November.

 

NanoString topped the 15 firms in the GWDN Index that saw a gain in their stock price in November, while Agilent led the decliners for the month.

Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.

 

CMS has issued its final payment decision for Exact Sciences' Cologuard test and will reimburse providers $502 per test.

NEW YORK (GenomeWeb) – Stocks in the omics research tools and molecular diagnostics space were mixed in August as the GenomeWeb Daily News Index moved up almost 3 percent from July, but nearly half of the firms in the index suffered a loss in share price month over month.

NEW YORK (GenomeWeb) – Investment banks Goldman Sachs and Leerink Partners initiated coverage of T2 Biosystems today with a Neutral and Market Perform rating, respectively, on the firm's stock.

NEW YORK (GenomeWeb) – In July the stocks of companies operating in the omics research tools and molecular diagnostics spaces returned almost all of their gains from June as the

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.

NEW YORK (GenomeWeb) – Stocks for firms in the omics and molecular diagnostics market provided a mixed bag for the month of May as the GenomeWeb Daily News Index saw a gain of 2 percent month over month.

NEW YORK (GenomeWeb News) – While 2013 was a very good year in general for the stock market, biotech stocks, including those of omics tools and molecular diagnostics firms, provided a particularly strong return for investors.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.